Loading company…
Develops pharmaceutical compounds that target misfolded proteins linked to neurodegenerative diseases such as Alzheimer's disease.
TREVENTIS Corporation designs pharmaceutical compounds aimed at misfolded proteins, which are linked to neurodegenerative diseases, using its Common Conformational Morphology technology. Its programs target conditions such as Alzheimer's disease and oncology, and it has a partnership with Takeda. Founded in 2008 and based in the US, the company is at the seed stage. It has closed two deals, most recently a USD 4.4 mn grant from Wellcome Trust on September 18, 2013, and reports a total of USD 0.55 mn raised.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in